HUMACYTE INC Share Price Today: Live Updates & Key Insights

HUMACYTE INC share price today is $0.625, up -2.16%. The stock opened at $0.6397 against the previous close of $0.6386, with an intraday high of $0.6464 and low of $0.6227.

HUMACYTE INC Share Price Chart

HUMACYTE INC

us-stock
To Invest in {{usstockname}}
us-stock

HUMACYTE INC Share Price Performance

$0.625 -0.0216(-2.16%) HUMA at 27 Jul 2026 03:30 PM Biotechnology
Lowest Today 0.6227
Highest Today 0.6464
Today’s Open 0.6397
Prev. Close 0.6386
52 Week High 2.76
52 Week Low 0.55
Day’s Range: Low 0.6227 High 0.6464
52-Week Range: Low 0.55 High 2.76
1 day return -
1 Week return -5.03
1 month return -14.71
3 month return -22.5
6 month return -38.19
1 year return -74.77
3 year return -78.47
5 year return -93.73
10 year return -

HUMACYTE INC Institutional Holdings

BlackRock Inc 4.57

Vanguard Group Inc 3.12

Vanguard Total Stock Mkt Idx Inv 2.86

Vanguard Capital Management, LLC 2.65

Antipodes Partners Limited 2.12

Great Point Partners LLC 1.39

Geode Capital Management, LLC 1.36

State Street Corp 1.13

UBS Group AG 1.03

Vanguard Institutional Extnd Mkt Idx Tr 0.79

Woodline Partners LP 0.74

AQR Capital Management LLC 0.71

Fidelity Small Cap Index 0.59

iShares Biotechnology ETF 0.54

Vanguard Portfolio Management, LLC 0.53

Charles Schwab Investment Management Inc 0.48

Northern Trust Corp 0.45

Russell 2000 Equity Index Fund B 0.43

Russell 2000 Index Non-Lendable Fund 0.43

Susquehanna International Group, LLP 0.39

Vanguard Fiduciary Trust Co 0.38

Schwab US Small-Cap ETF™ 0.32

LPL Financial Corp 0.32

Fidelity Extended Market Index 0.31

Private Advisor Group, LLC 0.31

The Goldman Sachs Group Inc 0.25

Lion Point Capital, LP 0.24

Vanguard Health Care ETF 0.21

Blackrock Extended Mkt Fund CF 0.18

BlackRock Extended Equity Market Fund K 0.16

XTX Topco Ltd 0.15

Schwab Small Cap Index 0.14

Extended Equity Market Fund B 0.12

Extended Equity Market Fund E 0.12

Fidelity Total Market Index 0.10

Invesco RAFI US 1500 Small-Mid ETF 0.09

Fidelity Series Total Market Index 0.09

Spartan Extended Market Index Pool F 0.09

NT Ext Equity Mkt Index Fund - Lending 0.08

iShares Russell 2000 Small-Cap Idx Instl 0.08

HUMACYTE INC Market Status

Strong Buy: 5

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

HUMACYTE INC Fundamentals

Market Cap 172.19 M

PB Ratio 14.9526

PE Ratio 0.0

Enterprise Value 190.74 M

Total Assets 116.37 M

Volume 2566605

HUMACYTE INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:6187000 6.2M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:-49000 -0.0M, FY20:null 0.0M, FY19:6187000 6.2M

Annual Net worth FY23:-89390000 -89.4M, FY22:64219000 64.2M, FY21:37536000 37.5M, FY20:-68726000 -68.7M, FY19:null 0.0M

Quarterly Revenue Q1/2026:495000 0.5M, Q3/2025:753000 0.8M, Q2/2025:301000 0.3M, Q1/2025:517000 0.5M, Q3/2024:0 0.0M

Quarterly Profit Q1/2026:-1543000 -1.5M, Q3/2025:493000 0.5M, Q2/2025:-1772000 -1.8M, Q1/2025:-1462000 -1.5M, Q3/2024:null 0.0M

Quarterly Net worth Q1/2026:-17619000 -17.6M, Q3/2025:-17510000 -17.5M, Q2/2025:-37658000 -37.7M, Q1/2025:39139000 39.1M, Q3/2024:-39202000 -39.2M

About HUMACYTE INC & investment objective

Company Information Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Organisation Biotechnology

Employees 184

Industry Biotechnology

CEO Dr. Laura E. Niklason M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

HUMACYTE INC FAQs

What is the share price of HUMACYTE INC today?

The current share price of HUMACYTE INC is $0.625.

Can I buy HUMACYTE INC shares in India?

Yes, Indian investors can buy HUMACYTE INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy HUMACYTE INC shares in India?

You can easily invest in HUMACYTE INC shares from India by:

Can I buy fractional shares of HUMACYTE INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of HUMACYTE INC?

HUMACYTE INC has a market cap of $172.19 M.

In which sector does HUMACYTE INC belong?

HUMACYTE INC operates in the Biotechnology sector.

What documents are required to invest in HUMACYTE INC stocks?

To invest, you typically need:

What is the PE and PB ratio of HUMACYTE INC?

The PE ratio of HUMACYTE INC is N/A and the PB ratio is 14.95.